Altimmune(US:ALT) Globenewswireยท2025-10-06 03:40Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6][7] Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Altimmune to contact them to discuss their legal options [1][9] - There is a deadline of October 6, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Altimmune [4][8] Group 2: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [6] - The stock price of Altimmune fell from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [7]